body fluids **of human subjects having or suspected of having cancer:** cerebrospinal fluid, urine, saliva, **[and]** sputum, **peritoneal fluid, pleural fluid and bronchial washings,** and determining the amount of lipid associated sialoprotein in a sample of such fluid which comprises the following steps:

a) adding to the sample a mixture of a chlorinated lower alkyl hydrocarbon and a lower alkyl alcohol;

b) mixing the resulting admixture for a suitable period of time to dissolve lipid-bound sialic acid in the sample in the chlorinated hydrocarbon/alcohol mixture;

c) centrifuging the mixture at **[high speed] about 6000 rpm** to form a substantially clear upper phase;

d) separately recovering from the clear upper phase so formed a predetermined volume of the upper phase;

e) adding to the predetermined volume of the upper phase an amount of a mixture of an aqueous protein-precipitating agent without any absorbing material, the amount of mixture being effective to cause precipitation of the lipid associated sialoprotein;

f) vortexing the resulting admixture;

g) centrifuging and recovering the resulting precipitate;

h) washing the precipitate in a saline solution;

i) centrifuging the resulting mixture;

j) dissolving the precipitate in water;

k) adding to the solution a hydrolysis agent;

l) heating the resulting admixture;

m) determining the amount of lipid associated sialoprotein present in the solution and thereby the amount present in the fluid sample.

Amend claim 17 as follows:

- -17. **Amended:** A method of diagnosing cancer in a human subject which comprises determining the amount of lipid associated sialoprotein in a sample of the subject's cerebrospinal fluid, **urine**, saliva, **[or]** sputum, **peritoneal fluid, pleural fluid or bronchial washings** according to the method of claim 1 and comparing the amount so determined with amounts previously obtained for subjects known to have cancer by use of the method of claim 1.

Amend claim 18 as follows:

- -18. **Amended:** A method of diagnosing cancer in a human subject which comprises determining at regular time intervals the amount of lipid associated sialoprotein in a sample of the subject's cerebrospinal fluid, **urine**, saliva **[or]** sputum **[sample]**, **peritoneal fluid, pleural fluid or bronchial washings**, according to the method of claim 1 and comparing the amounts so determined with amounts previously obtained for the subject by use of the method of claim 1.

Cancel Claim 19: in its entirety.